top of page

PROGRAMME Poster Presentations

Poster Session 01: Helicobacter 01

 

P01.01.

Comparison Of Standard Triple Therapy With Or Without Bismuth As An Initial Treatment For Helicobacter Pylori Infection

Seok-ryeol Choi, Busan, Korea, Republic of

 

P01.02.

Identification Of Potentially New Antiinfectives Against H. Pylori By Repurposing FDA-Approved Drugs

Dietmar Pfeiffer, Munich, Germany

 

P01.03.

The Efficacy Of Rifabutin-Based Helicobacter Pylori Eradication Regimen

Yuri Kim, Daegu, Korea, Republic of

 

P01.04.

Duodenogastric Reflux In helicobacter pylori infection And Re-Infection

Adriana Barrios, Quetzaltenango, Guatemala

 

P01.05.

The Widely Used 15% Clarithromycin Resistance Cut-Off Rule Fails To Predict H. Pylori Treatment Success Or Failure And Should Be Abandoned.

Selvi Thirumurthi, Houston, United States

 

P01.06.

Helicobacter Suis infection Induced Xenophagy And Apoptosis In Mouse Parietal Cells

Masahiko Nakamura, Isehara, Japan

 

P01.07.

Changes Of Metabolic Profile After Eradication Of helicobacter Pylori

Moon Kyung Joo, Seoul, Korea, Republic of

 

P01.08.

New In-Office H. Pylori Detection Device.

Miltiadis Moutzoukis, Ioannina, Greece

 

P01.09.

Brazilian Registry On H. Pylori Management(Hp-Brazilreg) Analysis Of 835 First-Line Empiric Treatments

Luiz Coelho, Belo Horizonte, Brazil

 

P01.10.

Brazilian Registry On H. Pylori Management (Hp-Brazilreg) Analysis Of 300 Empiric Second-Line And Rescue Treatments

Luiz Coelho, Belo Horizonte, Brazil

 

P01.11.

Effectiveness Of First-Line Treatment For H. Pylori Infection In Israel: Results From The European Registry On H. Pylori Management (Hp-EuReg).

Doron Boltin, Petah Tikva, Israel

 

P01.12.

Prescriptions And Effectiveness Are Influenced By Indications For Helicobacter Pylori Investigation: European Registry On H. Pylori Management (Hp-EuReg)

Samuel Martinez-Dominguez, Zaragoza, Spain

 

Poster Session 02: Helicobacter 02

 

P02.01.

Culture-Based Susceptibility-Guided Tailored Versus Empirical Concomitant Therapy As First-Line Helicobacter Pylori Treatment: A Randomized Clinical Trial

Byung-Hoon Min, Seoul, Korea, Republic of

 

P02.02.

Helicobacter Pylori Status Is Not Predictive Of Periodontal Disease

Marko Nikolic, Zagreb, Croatia

 

P02.03.

Diminishing Of Helicobacter Pylori Adhesion To Gastric Tissue Of Cavie Porcellus Inoculated With These Bacteria Due To Previous Inoculation With BCG Vaccine Mycobacteria

Weronika Gonciarz, Lódz, Poland

 

P02.04.

Spray Dried Ph Sensitive Chitosan Microparticles Loaded With Mycobacterium Bovis - BCG Intended For Supporting Treatment Of Helicobacter Pylori Infection

Weronika Gonciarz, Lódz, Poland

 

P02.05.

Assessment Of The Prevalence Of Significant Endoscopic Lesions In Patients Over 18 Years With Helicobacter Pylori Infection In A Center In North-East Romania

ELENA POPOVICI, BACAU, Romania

 

P02.06.

Prescribing Trends Of Helicobacter Pylori Eradication Treatment In Irish Primary Care From 2015 To 2019: A Cross-Sectional Analysis

Marta Dobric, Dublin, Ireland

 

P02.07.

Usefulness Of Antimicrobial Susceptibility Testing In The Eradication Treatment Of Patients With Two Or More Failed Helicobacter Pylori Eradication Treatments.

Mariko Hojo, Tokyo, Japan

 

P02.08.

Empirical First Line H. Pylori Eradication Therapy In Italy From 2013 To 2023: Effectiveness Results From The European Registry On H. Pylori Management (Hp-Eu-Reg)

Matteo Pavoni, Carrara, Italy

 

P02.09.

Change Of Treatment Pathway Of Helicobacter Pylori Infection After The Guideline Update: A Distributed Network Analysis Of Multi-Center Databases Using Common Data Model

Young woo Chae, Seoul, Korea, Republic of

 

P02.10.

Vonoprazan And Amoxicillin Dual Therapy For Helicobacter Pylori Infection In People Living With HIV

Jinzhi Zhang, Chengdu, China

 

P02.11.

Effectiveness Of First-Line Empirical Treatment In Portugal: Data From The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Maria Viegas, Coimbra, Portugal

 

Poster Session 03: Helicobacter 03

 

P03.01.

First-Line Prescription Patterns And Eradication Rates In Ireland Over A 10-Year Period: Data From The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Sinead Smith, Dublin, Ireland

 

P03.02.

Prevalence Of Primary Clarithromycin Resistance In Patients Infected With Helicobacter Pylori In Europe In The Last Four Decades

Olga Nyssen, Madrid, Spain

 

P03.03.

Seroprevalence Of H.Pylori In 25-64 Years Old Population In Lithuania

Limas Kupcinskas, Kaunas, Lithuania

 

P03.04.

Status Of The Helicobacter Pylori Screening At Our Institution Over Four Years

Kumiko Ueda, Tokyo, Japan

 

P03.05.

Comparative Efficacy & Safety Of Potassium-Competitive Acid Blocker (P-CAB) Based Dual, Triple And Quadruple Regimens For First Line H. Pylori Infection Treatment: A Systematic Review And Network Meta-Analysis.

Theodore Rokkas, Athens, Greece

 

P03.06.

Relationship Between The Presence Of Antibodies To The CAGA Of H.Pylori And The Stage Of Chronic Gastritis According To The OLGA System

Dmitry Bordin, Moscow, Russian Federation

 

P03.07.

Idiopathic Gastric Antral Ulcers

koji nakamichi, hukuoka, Japan

 

P03.08.

Real-World Efficacy Of Second-Line Therapies For helicobacter Pylori: A Population-Based Study

Wai Keung Leung, Hong Kong, Hong Kong

 

P03.09.

MUC5AC Expression In The Gastric Mucosa Of Helicobacter Pylori Positive Gastritis - A Systematic Review And Meta-Analysis

Yaron Niv, Ariel, Israel

 

P03.10.

Helicobacter Pylori Infection Recurrence In Developed Versus Developing Countries - A Systematic Review And Meta-Analysis

Yaron Niv, Ariel, Israel

 

P03.11.

Trends In The Prescription Of Eradication Treatments And Their Effectiveness In Naïve Patients Over 11 Years (2013-2023) In Europe: Data From The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Olga P. Nyssen, Madrid, Spain

 

P03.12.

Empirical Second-Line Treatments In Europe: Data From 9,000 Cases From The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Olga P. Nyssen, Madrid, Spain

Poster Session 04: Helicobacter 04

 

P04.01.

Effectiveness And Safety Of 1St Line Anti-H.Pylori Therapy In Ukraine (According To Hp-EuReg Data)

Oleksiy Gridnyev, Kharkiv, Ukraine

 

P04.02.

Helicobacter Pylori First-Line Empirical Therapy Effectiveness And Its Relationship To Antibiotic Consumption In The Community: Data From The European Registry On H. Pylori Management (Hp-EuReg).

Olga P. Nyssen, Madrid, Spain

 

P04.03.

Experience With Single-Capsule Bismuth Quadruple Therapy In 11,000 Patients From The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Olga P. Nyssen, Madrid, Spain

 

P04.04.

Effectiveness Of Single-Capsule Bismuth Quadruple Re-Treatment After Previous Failure With The Same Therapy: Results From The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Olga P. Nyssen, Madrid, Spain

 

P04.05.

Non-Bismuth Quadruple Concomitant Treatment For Helicobacter Pylori Eradication: Systematic Review And Meta-Analysis

Pablo Parra, Madrid, Spain

 

P04.06.

Empirical First-Line Prescriptions And Effectiveness Trends In Azerbaijan In The Period 2020-2023: Results From The European Registry On H. Pylori Management (Hp-EuReg)

Gulustan Babayeva, Baku, Azerbaijan

 

P04.07.

Helicobacter Pylori First- And Second-Line Empirical Prescriptions And Effectiveness In Lithuania During The Years 2013-2023: Analysis Of The European Registry On H. Pylori Management (Hp-EuReg)

Paulius Jonaitis, Kaunas, Lithuania

 

P04.08.

Prescriptions And Effectiveness Of 3,351 Empirical Rescue Therapies On Third And Subsequent Lines: Data From The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Olga P. Nyssen, Madrid, Spain

 

P04.09.

Updating Primary Antibiotic Resistance In H. Pylori Strains

Matteo Pavoni, Bologna, Italy

 

P04.10.

Gastric Acid Inhibition With Esomeprazole Or Pantoprazole In The Sequential Therapy For H. Pylori Eradication In Clinical Practice

Matteo Pavoni, Bologna, Italy

 

P04.11.

Fourteen-Day Amoxicillin Or Tetracycline Containing Bismuth Quadruple Therapy Versus 14-Day Metronidazole Based Triple Therapy As A First-Line Treatment For Clarithromycin Resistant Helicobacter Pylori Infection: A Multicenter Randomized Controlled Trial

Samryong Jee, Busan, Korea, Republic of

 

P04.12.

The Effectiveness Of First And Second Line Therapy In The Treatment Of Helicobacter Pylori - Data From A Greek Hospital.

Athanasios Kontos, Athens, Greece

 

P04.13.

Helicobacter Pylori Infection In Symptomatic Vietnamese Children: Prevalence, Antibiotic Resistance, And Treatment Implications

Tu Nguyen, Ho Chi Minh City, Viet Nam

 

Poster Session 05: Helicobacter 05

 

P05.01.

Genomic Analysis Of Signaling Pathways During Multistep Processes Of Helicobacter Pylori-Induced Gastric Cancer Development

Sung Eun Kim, Busan, Korea, Republic of

 

P05.02.

Evaluation Of The Effectiveness And Safety Of Helicobacter Pylori Empirical Eradication Regimens In Switzerland: An Interim Analysis With Data From The European Registry On H. Pylori Management (Hp-EuReg)

Olga P. Nyssen, Madrid, Spain

 

P05.03.

Distribution Of Antimicrobial MICs For Helicobacter Pylori Strains Over A Six-Year Period In Korean Patients From Seoul, Korea

JUNG MOGG KIM, Seoul, Korea, Republic of

 

P05.04.

Screening And Eradication Of helicobacter Pylori for Junior High School Students In Japan. Nationwide Survey For Local Governments Regarding Conducted Status And Methods.

Masumi Okuda, Nishinomiya, Japan

 

P05.05.

The Second Irish Helicobacter Pylori Working Group Consensus For The Diagnosis And Treatment Of Helicobacter Pylori Infection In Adult Patients In Ireland.

Sinead Smith, Dublin, Ireland

 

P05.06.

Preliminary Results Of The Follow-Up Of A GISTAR Study Participant Cohort

Danute Razuka-Ebela, Riga, Latvia

 

P05.07.

Use Of Self-Administered Rapid Stool Antigen Test For Monitoring After H. Pylori Eradication Therapy

Wai Keung Leung, Hong Kong, Hong Kong

 

P05.08.

Eradication Of Helicobacter Pylori Infection With The Help Of Autoprobiotics

Galina Alekhina, St-Petersburg, Russian Federation

 

P05.09.

Effectiveness Of The First-Line Eradication Therapy In 14 Cities In Russia: Results For The Period 2013-2022 Of The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Dmitriy Bordin, Moscow, Russian Federation

 

P05.10.

The Potential Use Of helicobacter Pylori Phages - What Do We Know So Far

Luís Melo, Braga, Portugal

 

P05.11.

Effectiveness Of Rebamipide-Containing First-Line Empirical Eradication Therapy In Russia: Results From The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Dmitry Bordin, Moscow, Russian Federation

 

P05.12.

The YAP/TAZ-Tead Pathway Controls Cytolethal Distending Toxin-Induced Dna Damage And Nuclear Remodeling In Intestinal Epithelial Cells

Lamia AZZI-MARTIN, Bordeaux, France

 

Poster Session 06: Helicobacter 06 

 

P06.01.

Increased Infiltration Of CD4+IL-17A+FOXP3+ T Cells In Helicobacter Pylori-Induced Gastritis

Yixian Guo, Shanghai, China

 

P06.02.

Helicobacter Pylori Associated Lesions Of The Upper Gastrointestinal Tract In Patients With Esophageal Dysphagia

Rashad Hasanov, Baku, Azerbaijan

 

P06.03.

Differential Accuracy Of Serology Test For The Diagnosis Of H. Pylori According To Age And Gastric Atrophy In A Large Scale Study

Jyh-Ming Liou, Taipei, Taiwan

 

P06.04.

Optimization Of Minocycline-Containing Bismuth Quadruple Therapy For Helicobacter Pylori Rescue Treatment: A Real-World Evidence Study

Hong Lu, Shanghai, China

 

P06.05.

Is Helicobacter Pylori Status Associated With Metachronous Gastric Cancer In Elderly Patients After Endoscopic Resection For Early Gastric Cancer?

Jong Yeul Lee, Goyang, Korea, Republic of

 

P06.06.

An Update Of The Helicobacter Pylori Diagnostic Tests And Indications For Treatment From The Latin American Registry On Helicobacter Pylori Management (Hp-LATAMreg).

Arnoldo Riquelme, Santiago, Chile

 

P06.07.

Interplay Of C-Terminal EPIYA-Repeats And NikS-Mediated Post-Transcriptional Regulation Of CagA mRNA

Fabrício de Melo, Vitória da Conquista, Brazil

 

P06.08.

Stool Antigen Test For Helicobacter Pylori Infection In Adults: A Meta-Analysis Of Diagnostic Test Accuracy

Fabrício Freire de Melo, Vitória da Conquista, Brazil

 

P06.09.

Most Frequent Helicobacter Pylori first-Line Empirical Eradication Therapies: Data From The Latin American Registry On H. Pylori Management (Hp-LATAMreg).

Arnoldo Riquelme, Santiago, Chile

 

P06.10.

Gastroprotective And Cytotoxic Effects Of Diacetylcurcumin And Its Metallic Derivatives

Almanelly Agabo-Martínez, Ciudad de Mexico, Mexico

 

P06.11.

World'S First Isolation Culture And Eradication Therapy Of Helicobacter Ailurogastricus In Human Patients

Masaya Sano, Kanagawa, Japan

 

P06.12.

Real-World Data At A High Volume Center In Republic Of Korea <: > The 1St-Line Regimens For The Eradication Of Helicobacter Pylori

Sung Kwan Shin, Seoul, Korea, Republic of

 

 

Poster Session 07: Helicobacter 07 

 

P07.01.

Differences Between Japan And Lithuania In Gastric Mucosal Damage And Gastric Cancer Profile Associated With H. Pylori Infection. A Lithuania-Japan International Collaborative Study.

Hideki Mori, Tokyo, Japan

 

P07.02.

Validation Of A Nearly Commercially Available In-House Selective Medium For The Isolation Of Helicobacter Pylori From Gastric Biopsies.

Véronique MIENDJE DEYI, Brussels, Belgium

 

P07.03.

Pin-Point Adaptive Differentiation Under Free Homologous Recombination In Helicobacter Pylori

Ichizo Kobayashi, Tokyo, Japan

 

P07.04.

Pcr-Guided Tailored Therapy In The Eradication Of Helicobacter Pylori: Experience From The European Registry On H. Pylori Management (Hp-EuReg)

Vladimir Milivojevic, Belgrade, Serbia

 

P07.05.

Molecular Resistance Of Helicobacter Pylori To Clarithromycin And Levofloxacin In Naive Patients In Moscow

Larisa Tsapkova, Moscow, Russian Federation

 

P07.06.

Antibiotic Resistance Evaluation Among Pcr-Tested Helicobacter Pylori Positive Patients: Results From The European Registry On H. Pylori Management (Hp-EuReg)

Vladimir Milivojevic, Belgrade, Serbia

 

P07.07.

Designer Non-Antibiotic Drug To Combat Helicobacter Pylori In The Age Of Antibiotic Resistance

Nicola Jones, Toronto, Canada

 

P07.08.

Effect Of Helicobacter Pylori Treatment On Clinical Outcomes In Patients With Gastrointestinal Bleeding Within 12 Months After Percutaneous Coronary Intervention - A Nationwide Population-Based Study

Beom Jin Kim, Seoul, Korea, Republic of

 

P07.09.

Cost Effectiveness Analysis Of Screening And Treatment Helicobacter Pylori Strategy For Preventing Gastric Cancer In Germany

Tianjun Song, Munich, Germany

 

P07.10.

Excellent Eradication Rate Of Once-Daily Vonoprazan, Levofloxacin, Clarithromycin-Mr, And Bismuth For H. Pylori Infection In High Clarithromycin And Metronidazole Resistance Area: A Prospective Randomized Study (Once-Vono Trial)

Ratha-korn Vilaichone, Pathumthani, Thailand

 

P07.11.

Helicobacter Pylori Infection And Pediatric Inflammatory Bowel Disease In A High Prevalence Country

Marta Tavares, Porto, Portugal

 

P07.12.

The Role Of Paraoxonase 1 In Helicobacter Induced Gastritis

Sung Soo Kim, Uijongbu, Korea, Republic of

 

Poster Session 08: Helicobacter 08 

 

P08.01.

Usefullness Of Helicobacter Pylori Salivary Antigen Test

Ayoung Lee, Ansan-si, Korea, Republic of

 

P08.02.

tba

Tatsiana Haurylenka, Gomel, Belarus

 

P08.03.

First-Line Empirical Therapy In The Uk: Interim Analysis From Data Of The European Registry On Helicobacter Pylori Management (Hp-EuReg)

Olga P. Nyssen, Madrid, Spain

 

P08.04.

tba

Tatsiana Haurylenka, Gomel, Belarus

 

P08.05.

Epithelial BMP Signaling Controls Tissue Response To Helicobacter Pylori Infection

Giulia Beccaceci, Berlin, Germany

 

P08.06.

Hydrogen Sulfide Donor Diminishes The Helicobacter Pylori-Induced Gastric Fibroblast Activation, Reducing The Risk Of Gastric Cancer Development

Gracjana Krzysiek-Maczka, Krakow, Poland

 

P08.07.

The Influence Of Macrolide Exposure On Tailored Helicobacter Pylori Eradication Therapy And Antibiotic Resistance Profiles: A Prospective Study Using The Drug Utilization Review System

Kee Don Choi, Seoul, Korea, Republic of

 

P08.08.

The Majority Of Complicated Peptic Ulcers Are Helicobacter Pylori-Associated, Among Which Clarithromycin-Resistant Infection Is Less Prevalent

Gábor Lotz, Budapest, Hungary

 

P08.09.

Validation Of An In-House Quantitative Real-Time Pcr Designed For Detection Of Helicobacter Pylori And Its Clarithromycin Resistance From Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Samples

Adrienn Biró, Budapest, Hungary

 

P08.10.

Differences In Success Rate Of Helicobacter Pylori Eradication According To Metronidazole Dose And Duration Of Use

So Young Byun, Seoul, Korea, Republic of

 

P08.11.

The Factors For Spontaneous Clearance Of Helicobacter Pylori After Subtotal Gastrectomy

So Young Byun, Seoul, Korea, Republic of

 

P08.12.

Practical Efficacy Of 1-Week Metronidazole Triple Regimen With Bismuth Add-On Compared To 2-Week Bismuth Quadruple Regimen For Clarithromycin-Resistant H Pylori Infection

Dae Young Cheung, Seoul, Korea, Republic of

 

Poster Session 09: Helicobacter 09 

 

P09.01.

Helicobacter Pylori Carrying Prophages: Winners In Fitness And Virulence?

Joana Vital, Lisboa, Portugal

 

P09.02.

Helicobacter And Campylobacter Species Commonly Colonize The Intestines Of Swine

Zeli Shen, Cambridge, United States

 

P09.03.

Are They Jumping? Detecting Spontaneous Prophageinduction In Helicobacter Pylori Strains

Luís Tanoeiro, Lisboa, Portugal

 

P09.04.

Only In A Minority Of Patients With Autoimmune Atrophic Gastritis, Helicobacter Pylori-Specific Genes Are Detectable In Gastric Biopsies

Edith Lahner, Roma, Italy

 

P09.05.

A Discordance In The Prevalence Of H. Pylori Infection In Bile Between H. Pylori-Specific-Stool-Antigen Test And PCR

YOSHIHISA FUKUDA, Fukuoka, Japan

 

P09.06.

First-Line Helicobacter Pylori Empirical Treatment In The Czech Republic (2019-2024): Initial Insights From The European Registry On H. Pylori Management (Hp-EuReg)

Jan Krivinka, Olomouc, Czech Republic

 

P09.07.

Using An IL-10-/--B6.129 Mouse Model To Study Helicobacter Cinaedi Induced Cellulitis And Bacteremia

Zeli Shen, Cambridge, United States

 

P09.08.

The Cap-Independent Translation Of Survivin 5’ Untranslated Region (5’UTR) And Viral IRES Sequences Is Inhibited By H. Pylori Infection In Gastric Cells

Manuel Valenzuela Valderrama, santiago, Chile

 

P09.09.

A Blind Randomized Controlled Clinical Trial On The Efficacy And Safety Of Helicobacter Pylori Eradication Therapy In A South-European Country

Elisa Gravito-Soares, Coimbra, Portugal

 

P09.10.

Management Of Helicobacter Pylori Infection In Spain Beyond The European Registry. Results Of A Nationwide Survey

Olga Nyssen, Madrid, Spain

 

P09.11.

Novel Insights Into The Ph-Gating Mechanism Of The Inner Membrane Urea Channel HpUrei From Helicobacter Pylori

Andreas Horner, Linz, Austria

 

P09.12.

Helicobacter Pylori Base-Excision Restriction Enzyme In Gastric Cancer

Masaki Fukuyo, Chiba, Japan

 

Poster Session 10: Helicobacter 10  

P10.01.

Novel Ligilactobacillus Salivarius Strains As Potential Probiotics In Helicobacter Pylori Eradication

Pirjo Spuul, Tallinn, Estonia

 

P10.02.

Helicobacter Pylori Treatment In Pakistan: Data From The Pakistan Registry On H. Pylori Management (Hp-PakistanReg)

Olga P. Nyssen, Madrid, Spain

 

P10.03.

Study Of Neutrophil Responses In Helicobacter Pylori Infection

Aristotelis Petris, Athens, Greece

 

P10.04.

The Case Of Gastric Metaplasia-Induced Duodenal Ulcer With H. Pylori Infection, Ultimately Leading To Death.

Jung Huh, Seoul, Korea, Republic of

 

P10.05.

Exploring General Practitioners' Practices And Perceptions Of helicobacter Pylori Infection

Charlene Deane, Dublin, Ireland

 

P10.06.

The Flagellar Structural Protein FliK Gene Affects The Biofilm Formation Of Helicobacter Pylori

Gangshi Wang, Beijing, China

 

P10.07.

Unveiling The Impact Of Chronic Gastric Helicobacter Infection On Mouse Hepatic Health

Sadia Khalid, Tallinn, Estonia

 

P10.08.

Exploring Cholesterol-Like Lipids As Bactericidal Decoys In The Fight Against Helicobacter Pylori

Ana Sofia Pinho, Porto, Portugal

 

P10.09.

Female Sex Is Associated With Helicobacter Pylori Clarithromycin Resistance And Treatment Failure

Thomas Butler, Dublin, Ireland

 

P10.10.

Efficacy Of Modified Levofloxacin-Based Regimen Following Bismuth Quadruple Therapy Failure For helicobacter Pylori Eradication In Korea

Ayoung Lee, Ansan, Korea, Republic of

 

P10.11.

Antimicrobial Resistance In Helicobacter Pylori Isolates: The Current Situation In Greece

Beatriz Martinez-Gonzalez, ATHENS, Greece

 

P10.12.

In Vitro Evaluation Of Antimicrobial Activity Against Helicobacter Pylori And Gastric Cytotoxicity Of Lipid Nanoparticles Coated With Chitosan

Bruna Almeida Furquim de Camargo, Araraquara, Brazil

 

Poster Session 11: Helicobacter 11  

 

P11.01.

Glycosylation Landscape Of Gastric Patient-Derived Organoids As A Model To Study The Role Of helicobacter Pylori Binding

Liliana Santos-Ferreira, Porto, Portugal

 

P11.02.

Targeting The Urease Activity To Assist In The Prevention Of H. Pylori Infections

Raushan Kumar, Porto, Portugal

 

P11.03.

One Week Vs. Two Weeks Vonoprazan Based Triple Regimen For Eradication Of H.Pylori: A Double Blind Randomized Trial A Randomized Non-Inferiority Placebo Controlled Trial

Shahab Abid, Karachi, Pakistan

 

P11.04.

Use Of Previously Cryopreserved, Clinically Normal, Gptdelta Mice Ablates Natural And Experimental Typhlocolitis Noted With H. Mastomyrinus Infection In Gpt Deltamice With Apparent Immunodeficiency

Amanda Armijo, Cambridge, United States

 

P11.05.

Immunological Changes Determined By Bismuth Quadruple Therapy In Patients With Helicobacter Pylori Infection

Elisa Gravito-Soares, Coimbra, Portugal

 

P11.06.

Investigating The Role Of Efflux Pump Gene Expression In Antimicrobial Resistant Helicobacter Pylori

Stephen Molloy, Dublin, Ireland

 

P11.07.

Two Birds, One Set Of Biopsies: The Use Of Pcr For The Diagnosis Of Helicobacter Pylori And Detection Of Resistance Using Biopsies From Bedside Rapid Urease Tests.

Stephen Molloy, Dublin, Ireland

 

P11.08.

Helicobacter Pylori RNA Metabolism: Identifying Vulnerabilities For Novel Antimicrobial Drug Discovery To Combat Drug-Resistant Infections

Jakub Skibinski, Lodz, Poland

 

Poster Session 12: Microbiota 01

 

P12.01.

Bacteria-Derived Extracellular Vesicles In Liquid Biopsy: Potential Biomarkers For Gastric Cancer Detection

Jae Gyu Kim, Seoul, Korea, Republic of

 

P12.02.

A Microbiome Testing-Based Personalized Approach To Treat Post-Infectious Irritable Bowel Syndrome: A Pilot Study

William Fusco, Rome, Italy

 

P12.03.

Active Bacterial Assemblages Throughout The Gastrointestinal Tract In Patients With Dementia

Kerstin Schütte, Osnabrück, Germany

 

P12.04.

Fecal Microbiota Transplantation In Irritable Bowel Syndrome: A Meta-Analysis Of Randomized Controlled Trials And Prospective Cohort Studies

Ratha-korn Vilaichone, Pathumthani, Thailand

 

P12.05.

Comparison Of Different Microbiome Analysis Pipelines And Their Reproducibility In The Determination Of The Composition Of The Microbiome Of The Gastric Mucosa.

Konrad Lehr, Magdeburg, Germany

 

P12.06.

Healthy Reference Range In Microbiome Diagnostics

Christina Casén, Oslo, Norway

 

P12.07.

Second Generation Antipsychotics Induced Weight Gain Associated With Microbiome Changes In Children And Young Adults

Alexandra Oros, Cluj-Napoca, Romania

 

P12.08.

Efficacy And Safety Of Fecal Microbiota Transplantation For The Treatment Of Severe And Severe-Complicated Clostridioides Difficile Infection: Report From A Large-Volume Fmt Center

Andrea Severino, Rome, Italy

 

P12.09.

Clinical Relevance Of Positive Molecular Stool Testing For Intestinal Pathogens In Different Gastrointestinal Disorders

Pierluigi Frasca, Roma, Italy

 

P12.10.

Clostridioides Difficile Infection In Our Patients With Inflammatory Bowel Disease

Skender Telaku, Prishtina, Kosovo, Republic of

 

 

Poster Session 13: Microbiota 02

 

P13.01.

Oral, Fecal And Blood Microbial Signature In Esophageal Cancer

Ho-Kyoung Lee, Seoungnam-si, Korea, Republic of

 

P13.02.

Phageome Profiling In Human Samples With Low Microbial Biomass

Joana Pereira-Marques, Porto, Portugal

 

P13.03.

Skeletal Muscle-Gut Axis: Emerging Molecular And Microbial Mechanisms Of Sarcopenia In Experimental Models Of Inflammatory Bowel Disease

Sara Troisi, Roma, Italy

 

P13.04.

Sarcopenia And IBD: Exploring Molecular Mechanisms And Potential Pharmacological And Microbial Modulators In In Vitro Models Of Inflammatory Bowel Disease

Sara Troisi, Roma, Italy

 

P13.05.

Targeting Gut Microbiome To Treat Recurrent Urinary-Tract Infections From Gut Pathobionts: A Pilot Study

Tommaso Rozera, Roma, Italy

 

P13.06.

Optimization Of A Metagenomics Protocol To Analyze Microbial Signatures In Cell-Free DANN

Melissa Mendes-Rocha, Porto, Portugal

 

P13.07.

A Machine Learning Algorithm To Identify Hidden Microbiome Metabolites In The Stomach

Luisa Portela, Porto, Portugal

 

P13.08.

Efficacy And Safety Of Fecal Microbiota Transplantation For The Treatment Of Clostridioides Difficile Infection: A 10-Year Experience Of A Large-Volume FMT Center

Marcello Fiorani, Rome, Italy

 

P13.09.

Evaluation Of Epithelial Cell Response To Commensal Bacteria In The Intestinal Organoid Model Of Ulcerative Colitis Patients

Jurgita Skieceviciene, Kaunas, Lithuania

 

P13.10.

Personalized Autoprobiotic Supplements Improve The Serum Metabolome And Gut Microbiome In Patients With Irritable Bowel Syndrome

Galina Alekhina, Saint Petersburg, Russian Federation

 

Poster Session 14: Microbiota 03 

 

P14.01.

Butyric Acid Counteracts H. Pylori Eradication-Induced Gut Microbiota Changes

Maria Markelova, Kazan, Russian Federation

 

P14.02.

"Influence Of Probiotics On Gut Microbiota In Genetic Mice Model Of Metabolic Syndrome"

Galina Alekhina, Saint-Petersburg, Russian Federation

 

P14.03.

Сomposition Of Intestinal Microbiocenosis In Children With Campylobacteriosis

Galina Alehina, Saint-Petersburg, Russian Federation

 

P14.04.

Autoprobiotics In Treatment Of Metabolic Syndrome

Galina Alekhina, Saint-Petersburg, Russian Federation

 

P14.05.

Therapeutic Modulation Of Gut Microbiome To Treat Immune-Checkpoint Inhibitors-Related Diarrhea And Colitis: Experience Of A Microbiome Clinic

Serena Porcari, Rome, Italy
 

P14.06.

Clostridium Difficile In Elderly: Challenging Topic

Rosa Ragozzino, Roma, Italy

 

P14.07.

Results Of A Regional Observational Retrospective Studies Of The Prevalence Of Small Intestinal Bacterial Overgrowth In Patients With digestive Diseases.

Valeriy Kryvy, Simferopol, Russian Federation

 

Poster Session 15: Cancer 01

 

P15.01.

Explainable Gastric Cancer Risk Prediction Of Machine Learning Based Models Trained On Data From Regular Health Check-Up Programs Of Screening Population

Ji Hyun Song, Seoul, Korea, Republic of

 

P15.02.

The Epidemiological Profile Of Gastric Cancer Patients In Groote Schuur Hospital Cape Town, South Africa.

Innocent Francis, Cape Town, South Africa

 

P15.03.

The Feasibility Of Diagnostic Endoscopic Resection For Grade 1-2 Gastric Neuroendocrine Tumors: A Single-Institutional Retrospective Analysis

Cheol Woong Choi, Yangsan, Korea, Republic of

 

P15.04.

The Role Of Glycosylation In Gastric Carcinogenesis And Tumour Progression

Joana Gomes, Porto, Portugal

 

P15.05.

Inflammatory Markers And Recurrence Of Metachronous Tumors After Curative Resection Of Early Gastric Cancer

Moon Kyung Joo, Seoul, Korea, Republic of

 

P15.06.

Helicobacter Pylori Infection Modulates Intestinal Homeostasis And Increases Colorectal Cancer Risk Depending On CagA

Veronika Engelsberger, Munich, Germany

 

P15.07.

Withdrawn

 

P15.08.

Key Indicators For Global Gastric Cancer Endoscopic Screening Programs: A Systematic Review And Meta-Analysis

Jiayue Wang, Shanghai, China

 

P15.09.

Polymorphism Of Apoptosis Marker Genes In The Blood Of Indigenous People With Gastric Cancer In The Republic Of Tyva

Vladislav Tsukanov, Krasnoyarsk, Russian Federation

 

P15.10.

Index Of Gastric Epitheliocytes Proliferationin Helicobacter Pylori-Positive Patients With Atrophic Gastritis Depending On The Presence Of High Or Low Degree Dysplasia

Vladislav Tsukanov, Krasnoyarsk, Russian Federation

 

P15.11.

Higher Frequency Of Gastric Neoplasia In Advanced Chronic Liver Disease Patients In Comparison To A Healthy Population: Impact Of Screening Endoscopy In An Intermediate Risk Country

Miguel Martins, Porto, Portugal

 

P15.12.

Biopsies Sampling In Helicobacter Pylori Negative Patients: Is It Still Worthy?

Matteo Pavoni, Bologna, Italy

 

Poster Session 16: Cancer 02

 

P16.01.

Gastric Adenocarcinoma Recurrence After Endoscopic Submucosal Dissection For Early Gastric Cancer

Jeong Seop Moon, Busan, Korea, Republic of

 

P16.02.

Gastric Cancer Treatment Target Identified From An Accelerated Helicobacter-Induced Gastric Cancer Mouse Model

Marygorret Obonyo, San Diego, United States

 

P16.03.

The Role Of MUC13 In Gastric Cancer Cell Death Inhibition And Dysbiosis

Baptiste Oosterlinck, Antwerp, Belgium

 

P16.04.

Gastric Cancer Risk According To OLGA And OLGIM Stages In The Family Members Of Gastric Cancer Patients

Il Ju Choi, Goyang, Korea, Republic of

 

P16.05.

Size Does Matter: The Choice Of Treatment Modality For Superficial Esophageal Cancer

Ji Hoon Yoon, Seoul, Korea, Republic of

 

P16.06.

A Prospective Comparative Study Of Magnifying Endoscopy With Narrow Band Imaging And Endoscopic Ultrasonography For Predicting Tumor Invasion Depth In Early Gastric Cancer

Jun Chul Park, Seoul, Korea, Republic of

 

P16.07.

Gastric Cancer Risk Among Immigrant And Socioeconomic Groups In The Netherlands

Duco Mülder, Rotterdam, Netherlands

 

P16.08.

Cell Extrusion Signatures In The Gastric Epithelium: A Crosstalk Between E-Cadherin And Filamin A

Soraia Melo, Porto, Portugal

 

P16.09.

E-Cadherin Dysfunction Modulates Structural Properties Of Nuclei In Gastric Cancer Cells

José Santos, Porto, Portugal

 

P16.10.

Clinical Significance Of Blood Urea Nitrogen As A Predictor Of Delayed Bleeding After Endoscopic Submucosal Dissection For Gastric Neoplasm

Beom Jin Kim, Seoul, Korea, Republic of

 

P16.11.

Optimized Endoscopic Surveillance Intervals For Detecting Progression Of Intestinal Metaplasia (IM): A Large Population-Based Study From Low Prevalence Area Of Gastric Cancer (IM-Surveillance Trial)

Ratha-korn Vilaichone, Pathumthani, Thailand

 

Poster Session 17: Cancer 03 

 

P17.01.

Risk Factor Analysis For Bleeding After Gastric Endoscopic Submucosal Dissection: A Nationwide Population-Based Study Over 11 Years

Jae Yong Park, Seoul, Korea, Republic of

 

P17.02.

Targeting The PI3K AKT mTORC1 Signaling Pathway In Gastric Cancer Stem Cells

Christine Varon, Bordeaux, France

 

P17.03.

Discovery And Validation Of Predictive Markers For Metachronous Gastric Cancer Development After Endoscopic Resection Of Early Gastric Cancer

Bokyung Kim, Seoul, Korea, Republic of

 

P17.04.

Microbiome-Derived Kynurenine Is A New Player In Gastric Cancer

Inês Castro, Porto, Portugal

 

P17.05.

Colorectal Cancer And Gut Microbiota: Possibilities Of Autoprobiotics In Complex Treatment

Galina Alekhina, St-Petersburg, Russian Federation

 

P17.06.

The Role Of Helicobacter Pylori, Cytotoxin-Associated Gene A CagA In Autophagic Pathways Of Gastric Epithelial Cells

Yong Chan Lee, Seoul, Korea, Republic of

 

P17.07.

Blood Plasma Cell-Free DNA Molecular Landscape In Gastric Cancer

Greta Varkalaite, Kaunas, Lithuania

 

P17.08.

Elevated Bacterial Load And Attenuated Immune Response Observed In Tnfsf14-Deficient Mice Upon Helicobacter Pylori Infection.

Anja Mühlbauer, Munich, Germany

 

P17.09.

Targeted Screening For Gastric Cancer; A Combined Approach

Charlene Deane, Dublin, Ireland

 

P17.10.

How Well OLGA And OLGIM Stages Can Predict Gastric Cancer?

Paula Naļivaiko, Riga, Latvia

 

P17.11.

Helicobacter Pylori Infection Induces Gastric Precancerous Lesions And Persistent Expression Of Angpt2, Vegf-A And Tnf-A In A Mouse Model

Wendy Malespín-Bendaña, San Pedro de Montes de Oca, Costa Rica

 

P17.12.

Mycobiome Profile Alterations In Gastric Tissue Of Gastric Cancer Patients

Darja Nikitina, Kaunas, Lithuania

bottom of page